RxNews Recap for Monday 12-07-09 Print E-mail
By Mary Davila   
Monday, 07 December 2009 23:28

Below is a list of the companies that made news in the healthcare sector on Monday, December 07, 2009.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.

ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat senere medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

Gentium S.p.A. (Nasdaq: GENT) today announced the resignation of Dr. Francesco Bellini as Chairman and a member of Gentium’s Board of Directors who indicated that his other business commitments prevented him from continuing to devote adequate time to Gentium. Dr. Bellini was elected to Gentium’s Board in October 2009.

Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life sciences industry, today introduced Scepter™, the industry’s first handheld, automated cell counter, at the American Society of Cell Biology Annual Meeting in San Diego.

The Dow Chemical Company (NYSE: DOW) today announced that it has formed a new independent company that will be known as Pfenex Inc.1 through its Dow Venture Capital group.

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE) today announced its entry into the flow cytometry instrumentation market with the debut of the Attune™ Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells.

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into a definitive agreement with Socius Life Sciences Capital Group, LLC.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today it has purchased a Labcyte POD(TM) 810 plate assembler equipped with an Echo(R) 555 acoustic liquid handler for its work in high- throughput screening and secondary screening.

Ventana Biotech Inc. ("Ventana") (PINK SHEETS:VNTA), a biotechnology company developing an appetite-suppressing and stress reducing chewing gum,today announced that it has entered into the final stages of negotiations for the sale of its current IP and product pipeline.

AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

BioMed Realty Trust, Inc. (NYSE:BMR) announced today that the company has increased the borrowing capacity on its unsecured line of credit by an additional $55 million.

PolyMedix, Inc. (OTC BB: PYMX) an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.

Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE) today announced its entry into the flow cytometry instrumentation market with the debut of the Attune™ Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for Tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Nyloxin OTC, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, a prescription treatment for severe (Stage 3) chronic pain.

Dyadic International, Inc. (Pink Sheets: DYAI) (“Dyadic”) today announced that Michael J. Faby will join Dyadic as its new Vice President Finance effective January 4, 2010.

Aspen Technology, Inc. (OTC: AZPN.PK), a leading provider of software and services to the process industries, today announced the release of aspenONE V7 software in nine languages -- Chinese, French, German, Italian, Japanese, Korean, Portuguese, Russian and Spanish -- adding to the existing English language version.

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) (OTCBB: ADMP) on December 4, 2009.

Affymetrix, Inc. (Nasdaq: AFFX) announced today the addition of Andrew J. Last, PhD, to its management team as Chief Commercial Officer.

Celgene International Sàrl (NASDAQ:CELG) announced that data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with relapsed chronic lymphocytic leukaemia (CLL) were presented during the 51st American Society of Hematology annual meeting in New Orleans, LA.

Stericycle, Inc. (NASDAQ:SRCL), announced today that it had completed its pending acquisition of MedServe, Inc., which is now a wholly-owned subsidiary of Stericycle’s.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter